Buzzreach and Taimei Intelligence Form Strategic Partnership to Expand Japan's Attraction of Cross-Border International Clinical Trials and Build a Clinical Trial Promotion Infrastructure
NQ Score
87/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Buzzreach, a clinical trial support company, and Taimei Intelligence have formed a strategic partnership to strengthen cross-border international clinical trials between Japan and China. By leveraging AI and patient data, they aim to streamline patient recruitment and accelerate drug development.
AI Analysis
Frequently Asked Questions
- Q: What is the main goal of this partnership?
- A: To streamline cross-border clinical trials between Japan and China and promote trial attraction to Japan using AI and data.
- Q: Which AI platform is being used?
- A: Trialnet, developed by Shengxin Medical, a subsidiary of Taimei, leveraging over 400,000 Chinese patient records.
- Q: What therapeutic areas are targeted?
- A: Oncology, autoimmune diseases, hematological disorders, dermatology, rare diseases, and infectious diseases.
- Q: What is the patient recruitment advantage?
- A: Rapid and accurate patient referral in Japan through regional medical networks and a proprietary platform.
- Q: What are the future plans?
- A: Launch first joint MRCT in oncology, with expansion to other indications and regions planned.